The FDA has recently given orphan drug designation to Ketamine for treatment of Amyotrophic Lateral Sclerosis (ALS)
Tocilizumab, an established rheumatoid arthritis (RA) treatment, was found to reduce inflammation in ALS patients in a new study.
A new study published in the Journal of Cell Biology has linked a defect in cholesterol metabolism to the development of neurological damage caused by amyotrophic lateral sclerosis (ALS).
A new study shows that erenumab is helpful in treating headaches and migraine in patients by blocking a certain protein in the body.
Atogepant, a prospective drug currently being developed by AbbVie, lowered migraine days in a recent study and showed optimistic results.
A new study published in The Journal of Headache and Pain has aimed to examine the relationship between headaches and COVID-19.
Johnson and Johnson’s new drug to treat multiple sclerosis, Ponvory, has performed well in a recent study compared to a similar MS drug.
The FDA recently approved a Phase II clinical trial which aims to treat MS patients using autologous adipose-derived mesenchymal stem cell infusions
A new study has found that undergoing cognitive rehabilitation is effective at restoring cognition in individuals with MS.
A new study published in the Multiple Sclerosis Journal has found that several common symptoms of MS often cluster together for patients in their first year following diagnosis
A new study on an anti-seizure drug specifically for newborns shows promise, though further research is needed.
A new study has determined that long-term video EEG monitoring is an effective diagnostic tool for epilepsy in children.
A recent study found that having an inherited cerebral cavernous malformation increases an individual’s risk of seizures.
NICE issued a draft guidance recommending the use of risdiplam as a new drug treatment for spinal muscular atrophy (SMA)
Spinal muscular atrophy is a debilitating rare illness, but advances in gene therapy might prove to be the future of treatment.
A new, more streamlined method of administration has recently been developed for the use of nusinersen in Spinal muscular atrophy (SMA).
A pilot program in Australia looked at at the importance of testing for spinal muscular atrophy (SMA) in newborns.
A recent review has underlined the prevalence of sleep disorders among patients with type 2 diabetes and its impact on health outcomes.
A study conducted at the Cleveland Clinic suggests some sleep disorders may be linked to more severe outcomes from COVID-19
The FDA has approved Xywav - a new treatment for idiopathic hypersomnia (an uncommon disorder that causes constant daytime sleepiness).